Qiagen N.V. (QGEN)
NYSE
Price as at 30 Sept 2026, 23:56 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Qiagen N.V. trades at $43.76. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Politician trades in QGEN
We hold 7 disclosed trades in QGEN by members of Congress and executive-branch officials. The latest 5:
- Alan S. Lowenthal · HouseSell · $1,001 - $15,000 · traded 8 Oct 2019 · disclosed 8 Nov 2019
- Alan S. Lowenthal · HouseSell · $15,001 - $50,000 · traded 8 Oct 2019 · disclosed 8 Nov 2019
- Alan S. Lowenthal · HouseBuy · $1,001 - $15,000 · traded 13 Sept 2019 · disclosed 21 Sept 2019
- Alan S. Lowenthal · HouseBuy · $1,001 - $15,000 · traded 13 Sept 2019 · disclosed 21 Sept 2019
- Alan S. Lowenthal · HouseBuy · $1,001 - $15,000 · traded 12 Sept 2019 · disclosed 21 Sept 2019
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Where does SteadyShares get its QGEN data?
Fundamentals for QGEN come from company filings and exchange data, as listed on NYSE; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 23:56 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for QGEN, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.